VENTANA PD-L1 (SP142) assay is the first and only FDA-approved assay for mTNBC*. Testing for PD-L1 identifies patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC**
This video is intended for US healthcare professionals.
US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Diagnostics Corp. discusses on:
1. How the assay is used in TNBC
2. System used for staining (1:00)
3. Scoring algorithm (1:42)
4. Tumor area definition (1:59)
5. Specimen requirement (2:10)
6. Case review microscopy session (4:30)
For questions, comments, or study ideas please contact your U.S. medical and scientific affairs managers or email us at indianapolis.msa@roche.com
MC-US-04269